引言：胃肠道癌症中的个性化医疗 - Suppr

Suppr

超能文献

Introduction: personalized medicine in gastrointestinal cancer.

作者信息

Riall Taylor S

机构信息

Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555-0541, USA.

出版信息

J Gastrointest Surg. 2012 Sep;16(9):1639-40. doi: 10.1007/s11605-012-1948-9. Epub 2012 Jun 30.

DOI:10.1007/s11605-012-1948-9

PMID:22752473

Abstract

摘要

相似文献

Introduction: personalized medicine in gastrointestinal cancer.

J Gastrointest Surg. 2012 Sep;16(9):1639-40. doi: 10.1007/s11605-012-1948-9. Epub 2012 Jun 30.

Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors.

Int J Mol Sci. 2023 Sep 19;24(18):14283. doi: 10.3390/ijms241814283.

Special Series: Advances in GI Cancer.

J Clin Oncol. 2015 Jun 1;33(16):1717-20. doi: 10.1200/JCO.2015.60.8661. Epub 2015 Apr 27.

Biomarkers for personalized medicine in GI cancers.

Mol Aspects Med. 2015 Nov;45:14-27. doi: 10.1016/j.mam.2015.06.002. Epub 2015 Jun 6.

Overview of personalized medicine in GI cancers.

J Gastrointest Surg. 2012 Sep;16(9):1641-4. doi: 10.1007/s11605-012-1949-8. Epub 2012 Jun 29.

[Personalized tumor therapy for gastrointestinal tumors].

Internist (Berl). 2015 Sep;56(9):1069-78. doi: 10.1007/s00108-015-3752-6.

[Gastrointestinal stromal tumors (GIST)].

Dtsch Med Wochenschr. 2013 Oct;138(40):2013-6. doi: 10.1055/s-0033-1349575. Epub 2013 Sep 24.

Biomarkers in gastrointestinal cancers.

Am J Gastroenterol. 2008 Aug;103(8):2106-10. doi: 10.1111/j.1572-0241.2008.01994.x. Epub 2008 Jul 12.

Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?

Best Pract Res Clin Endocrinol Metab. 2023 Sep;37(5):101794. doi: 10.1016/j.beem.2023.101794. Epub 2023 Jun 28.

[Gastrointestinal stromal tumors].

Dtsch Med Wochenschr. 2003 Sep 26;128(39):2015-9. doi: 10.1055/s-2003-42552.

引用本文的文献

From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.

Tumour Biol. 2014 Sep;35(9):8471-82. doi: 10.1007/s13277-014-2367-1. Epub 2014 Jul 26.

本文引用的文献

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

J Clin Oncol. 2011 Apr 1;29(10):1261-70. doi: 10.1200/JCO.2010.30.1366. Epub 2011 Mar 7.

The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program.

Hered Cancer Clin Pract. 2010 Nov 22;8(1):9. doi: 10.1186/1897-4287-8-9.

Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels.

Curr Opin Oncol. 2010 Jul;22(4):336-41. doi: 10.1097/CCO.0b013e32833a6b8e.

Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy.

Curr Oncol Rep. 2010 May;12(3):175-85. doi: 10.1007/s11912-010-0101-8.

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

J Clin Oncol. 2009 Apr 10;27(11):1806-13. doi: 10.1200/JCO.2008.17.7188. Epub 2009 Mar 9.

More controversy than ever - challenges and promises towards personalized treatment of gastric cancer.

Ann Surg Oncol. 2008 Apr;15(4):956-60. doi: 10.1245/s10434-007-9798-5. Epub 2008 Jan 23.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

Ann Oncol. 2008 Mar;19(3):508-15. doi: 10.1093/annonc/mdm496. Epub 2007 Nov 12.

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.

Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD003805. doi: 10.1002/14651858.CD003805.pub2.

Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations.

N Engl J Med. 2007 Oct 11;357(15):1555-6; author reply 1556.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

BMC Cancer. 2007 Aug 8;7:153. doi: 10.1186/1471-2407-7-153.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Introduction: personalized medicine in gastrointestinal cancer.

J Gastrointest Surg. 2012 Sep;16(9):1639-40. doi: 10.1007/s11605-012-1948-9. Epub 2012 Jun 30.

Towards Personalized Treatment and Molecular Research on Gastrointestinal Tumors.

Int J Mol Sci. 2023 Sep 19;24(18):14283. doi: 10.3390/ijms241814283.

Special Series: Advances in GI Cancer.

J Clin Oncol. 2015 Jun 1;33(16):1717-20. doi: 10.1200/JCO.2015.60.8661. Epub 2015 Apr 27.

Biomarkers for personalized medicine in GI cancers.

Mol Aspects Med. 2015 Nov;45:14-27. doi: 10.1016/j.mam.2015.06.002. Epub 2015 Jun 6.

Overview of personalized medicine in GI cancers.

J Gastrointest Surg. 2012 Sep;16(9):1641-4. doi: 10.1007/s11605-012-1949-8. Epub 2012 Jun 29.

[Personalized tumor therapy for gastrointestinal tumors].

Internist (Berl). 2015 Sep;56(9):1069-78. doi: 10.1007/s00108-015-3752-6.

[Gastrointestinal stromal tumors (GIST)].

Dtsch Med Wochenschr. 2013 Oct;138(40):2013-6. doi: 10.1055/s-0033-1349575. Epub 2013 Sep 24.

Biomarkers in gastrointestinal cancers.

Am J Gastroenterol. 2008 Aug;103(8):2106-10. doi: 10.1111/j.1572-0241.2008.01994.x. Epub 2008 Jul 12.

Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?

Best Pract Res Clin Endocrinol Metab. 2023 Sep;37(5):101794. doi: 10.1016/j.beem.2023.101794. Epub 2023 Jun 28.

[Gastrointestinal stromal tumors].

Dtsch Med Wochenschr. 2003 Sep 26;128(39):2015-9. doi: 10.1055/s-2003-42552.

引用本文的文献

From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.

Tumour Biol. 2014 Sep;35(9):8471-82. doi: 10.1007/s13277-014-2367-1. Epub 2014 Jul 26.

本文引用的文献

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

J Clin Oncol. 2011 Apr 1;29(10):1261-70. doi: 10.1200/JCO.2010.30.1366. Epub 2011 Mar 7.

The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program.

Hered Cancer Clin Pract. 2010 Nov 22;8(1):9. doi: 10.1186/1897-4287-8-9.

Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels.

Curr Opin Oncol. 2010 Jul;22(4):336-41. doi: 10.1097/CCO.0b013e32833a6b8e.

Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy.

Curr Oncol Rep. 2010 May;12(3):175-85. doi: 10.1007/s11912-010-0101-8.

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

J Clin Oncol. 2009 Apr 10;27(11):1806-13. doi: 10.1200/JCO.2008.17.7188. Epub 2009 Mar 9.

More controversy than ever - challenges and promises towards personalized treatment of gastric cancer.

Ann Surg Oncol. 2008 Apr;15(4):956-60. doi: 10.1245/s10434-007-9798-5. Epub 2008 Jan 23.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

Ann Oncol. 2008 Mar;19(3):508-15. doi: 10.1093/annonc/mdm496. Epub 2007 Nov 12.

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.

Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD003805. doi: 10.1002/14651858.CD003805.pub2.

Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations.

N Engl J Med. 2007 Oct 11;357(15):1555-6; author reply 1556.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

BMC Cancer. 2007 Aug 8;7:153. doi: 10.1186/1471-2407-7-153.